163 related articles for article (PubMed ID: 36353562)
1. Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients.
Muendlein A; Severgnini L; Decker T; Heinzle C; Leiherer A; Geiger K; Drexel H; Winder T; Reimann P; Mayer F; Nonnenbroich C; Dechow T
Front Oncol; 2022; 12():1045995. PubMed ID: 36353562
[TBL] [Abstract][Full Text] [Related]
2. Circulating Glypican-4 Is a Predictor of 24-Month Overall Survival in Metastatic Breast Cancer.
Muendlein A; Heinzle C; Brandtner EM; Leiherer A; Drexel H; Dechow T; Decker T
Oncol Res Treat; 2023; 46(4):151-156. PubMed ID: 36750040
[TBL] [Abstract][Full Text] [Related]
3. Circulating glypican-4 is a new predictor of all-cause mortality in patients with heart failure.
Muendlein A; Heinzle C; Leiherer A; Brandtner EM; Geiger K; Gaenger S; Fraunberger P; Mader A; Saely CH; Drexel H
Clin Biochem; 2023 Nov; 121-122():110675. PubMed ID: 37844682
[TBL] [Abstract][Full Text] [Related]
4. Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer.
Szarvas T; Reis H; Vom Dorp F; Tschirdewahn S; Niedworok C; Nyirady P; Schmid KW; Rübben H; Kovalszky I
Prostate; 2016 Aug; 76(11):977-85. PubMed ID: 27062540
[TBL] [Abstract][Full Text] [Related]
5. Serum glypican-4 is a marker of future vascular risk and mortality in coronary angiography patients.
Muendlein A; Brandtner EM; Leiherer A; Geiger K; Heinzle C; Gaenger S; Fraunberger P; Mader A; Saely CH; Drexel H
Atherosclerosis; 2022 Mar; 345():33-38. PubMed ID: 35202959
[TBL] [Abstract][Full Text] [Related]
6. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer.
Szarvas T; Reis H; Kramer G; Shariat SF; Vom Dorp F; Tschirdewahn S; Schmid KW; Kovalszky I; Rübben H
Hum Pathol; 2014 Apr; 45(4):674-82. PubMed ID: 24656090
[TBL] [Abstract][Full Text] [Related]
7. Serum and tissue syndecan-1 levels in renal cell carcinoma.
Niedworok C; Kempkensteffen C; Eisenhardt A; Tschirdewahn S; Rehme C; Panic A; Reis H; Baba H; Nyirády P; Hadaschik B; Kovalszky I; Szarvas T
Transl Androl Urol; 2020 Jun; 9(3):1167-1176. PubMed ID: 32676400
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis.
Qiao W; Liu H; Guo W; Li P; Deng M
Eur J Surg Oncol; 2019 Jul; 45(7):1132-1137. PubMed ID: 30598194
[TBL] [Abstract][Full Text] [Related]
9. Loss of SDC1 Expression Is Associated with Poor Prognosis of Colorectal Cancer Patients in Northern China.
Li K; Li L; Wu X; Yu J; Ma H; Zhang R; Li Y; Wang W
Dis Markers; 2019; 2019():3768708. PubMed ID: 31182980
[TBL] [Abstract][Full Text] [Related]
10. Serum glypican-4 is associated with the 10-year clinical outcome of patients with peripheral artery disease.
Muendlein A; Heinzle C; Leiherer A; Geiger K; Brandtner EM; Gaenger S; Fraunberger P; Saely CH; Drexel H
Int J Cardiol; 2022 Dec; 369():54-59. PubMed ID: 35944770
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of the ratio of carcinoembryonic antigen concentration to maximum tumor diameter in patients with stage II colorectal cancer.
Li X; Xiong Z; Xie M; Huang Q; Jin L; Yin S; Chen S; Lan P; Lian L
J Gastrointest Oncol; 2021 Aug; 12(4):1470-1481. PubMed ID: 34532103
[TBL] [Abstract][Full Text] [Related]
12. Association of Preoperative and Postoperative Plasma Syndecan-1 and Colorectal Cancer Outcome.
Tanaka H; Hayashi H; Tomita H; Tokumaru Y; Fukada M; Tajima JY; Yokoi R; Tsuchiya H; Kuno M; Sato Y; Yasufuku I; Asai R; Mori R; Tanaka Y; Okumura N; Futamura M; Matsuhashi N
Anticancer Res; 2024 Apr; 44(4):1611-1618. PubMed ID: 38537984
[TBL] [Abstract][Full Text] [Related]
13. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
14. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer.
Szarvas T; Sevcenco S; Módos O; Keresztes D; Nyirády P; Kubik A; Romics M; Kovalszky I; Reis H; Hadaschik B; Shariat SF; Kramer G
Urol Oncol; 2018 Jun; 36(6):312.e9-312.e15. PubMed ID: 29628317
[TBL] [Abstract][Full Text] [Related]
15. Soluble syndecan-1 as marker of intestinal inflammation: A preliminary study and evaluation of a new panel of biomarkers for non-invasive prediction of active ulcerative colitis.
Floer M; Clausen M; Meister T; Vollenberg R; Bettenworth D; Tepasse PR
Adv Clin Exp Med; 2021 Jul; 30(7):655-660. PubMed ID: 34286513
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patients.
Wang L; Zhou S; Zhang W; Wang J; Wang M; Hu X; Liu F; Zhang Y; Jiang B; Yuan H
Int J Colorectal Dis; 2019 Apr; 34(4):589-597. PubMed ID: 30627849
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Lee MA
Asia Pac J Clin Oncol; 2018 Jun; 14(3):239-246. PubMed ID: 29044941
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
Jürgensmeier JM; Schmoll HJ; Robertson JD; Brooks L; Taboada M; Morgan SR; Wilson D; Hoff PM
Br J Cancer; 2013 Apr; 108(6):1316-23. PubMed ID: 23449351
[TBL] [Abstract][Full Text] [Related]
19. The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.
Chida K; Kotani D; Masuishi T; Kawakami T; Kawamoto Y; Kato K; Fushiki K; Sawada K; Kumanishi R; Shirasu H; Matsubara Y; Yuki S; Komatsu Y; Yamazaki K; Yoshino T
Oncologist; 2021 Oct; 26(10):845-853. PubMed ID: 34232546
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients.
Gharbaran R; Goy A; Tanaka T; Park J; Kim C; Hasan N; Vemulapalli S; Sarojini S; Tuluc M; Nalley K; Bhattacharyya P; Pecora A; Suh KS
J Hematol Oncol; 2013 Aug; 6():62. PubMed ID: 23988031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
